| Literature DB >> 26833210 |
Yun Kyoung Kim1, Mi Yeong Hwang2, Young Jin Kim3, Sanghoon Moon4, Sohee Han5, Bong-Jo Kim6.
Abstract
BACKGROUND: The genetic contribution to complex diseases or traits, including cardio-metabolic traits, has been elucidated recently by large-scale genome-wide association studies. These genome-wide association studies have indicated that most pleiotropic loci contain genes associated with lipids. Clinically, lipid related abnormalities are strongly associated with other diseases such as type 2 diabetes, coronary artery disease and hypertension. The aim of this study was to evaluate the shared genetic background of lipids and other cardio-metabolic traits.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26833210 PMCID: PMC4736473 DOI: 10.1186/s12933-016-0337-1
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Fig. 1Overlap of loci associated with different lipids. This Venn diagram illustrates the name of lipid-associated loci that replicated in our study (P < 3.70 × 10−4)
Results of meta-analyses for associations between lipid loci and cardio-metabolic traits
| Category | Trait | CHR | SNP | Position | Gene | Function | A1/A2 | MAF | Effect size (beta ± s.e.) |
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glycemic traits (n = 13,378) | FPG | 2 | rs780093 | 27742603 |
| Intronic | G/A | 0.456 | 0.73 ± 0.13 | 6.26 × 10−9 | 0.72 (0.64) |
| 11 | rs174547 | 61570783 |
| Intronic | G/A | 0.319 | −0.70 ± 0.13 | 1.71 × 10−7 | 0.94 (0.12) | ||
| 11 | rs174570 | 61597212 |
| Intronic | A/G | 0.319 | −0.71 ± 0.13 | 1.09 × 10−7 | 0.97 (0.07) | ||
| 12 | rs3782886 | 112110489 |
| Nonsynonymous | G/A | 0.167 | −0.90 ± 0.17 | 7.21 × 10−8 | 0.67 (0.79) | ||
| 12 | rs11066015 | 112168009 |
| Intronic | A/G | 0.158 | −0.92 ± 0.17 | 5.93 × 10−8 | 0.74 (0.60) | ||
| 12 | rs671 | 112241766 |
| Nonsynonymous | A/G | 0.157 | −0.96 ± 0.17 | 2.00 × 10−8 | 0.80 (0.44) | ||
| HbA1c | 6 | rs1799945 | 26091179 |
| Nonsynonymous | G/C | 0.045 | −0.06 ± 0.01 | 4.57 × 10−5 | – | |
| Blood pressure (n = 10,310) | SBP | 12 | rs3782886 | 112110489 |
| Nonsynonymous | G/A | 0.167 | −1.34 ± 0.31 | 1.50 × 10−5 | 0.04 (4.15) |
| 12 | rs11066015 | 112168009 |
| Intronic | A/G | 0.158 | −1.53 ± 0.32 | 1.33 × 10−6 | 0.03 (4.50) | ||
| 12 | rs671 | 112241766 |
| Nonsynonymous | A/G | 0.157 | −1.49 ± 0.32 | 2.72 × 10−6 | 0.05 (4.01) | ||
| DBP | 12 | rs3782886 | 112110489 |
| Nonsynonymous | G/A | 0.167 | −0.78 ± 0.20 | 1.02 × 10−4 | 0.49 (0.48) | |
| 12 | rs11066015 | 112168009 |
| Intronic | A/G | 0.158 | −0.82 ± 0.21 | 7.12 × 10−5 | 0.41 (0.67) | ||
| 12 | rs671 | 112241766 |
| Nonsynonymous | A/G | 0.157 | −0.80 ± 0.21 | 1.09 × 10−4 | 0.47 (0.52) | ||
| Obesity (n = 13,378) | BMI | 16 | rs1421085 | 53800954 |
| Intronic | G/A | 0.125 | 0.29 ± 0.06 | 1.84 × 10−7 | 0.70 (0.71) |
| WHR | 5 | rs3846662 | 74651084 |
| Intronic | A/G | 0.476 | 0.003 ± 0.001 | 3.69 × 10−4 | 0.29 (2.45) | |
| 12 | rs3782886 | 112110489 |
| Nonsynonymous | G/A | 0.167 | −0.004 ± 0.001 | 3.45 × 10−5 | 0.12 (4.32) | ||
| 12 | rs11066015 | 112168009 |
| Intronic | A/G | 0.158 | −0.005 ± 0.001 | 3.35 × 10−6 | 0.13 (4.14) | ||
| 12 | rs671 | 112241766 |
| Nonsynonymous | A/G | 0.157 | −0.005 ± 0.001 | 2.87 × 10−6 | 0.13 (4.10) |
A threshold of association significance after correction for multiple testing is P < 3.70 × 10−4
CHR chromosome, A1/A2 minor allele/major allele, MAF minor allele frequency, n number of participants, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c Glycated hemoglobin, BMI body mass index, WHR waist-hip ratio; All of analyses were adjusted by age and sex. s.e. standard error, P P value from meta-analyses using the results from three cohorts, P P value from test of heterogeneity, Q Cochrane’s Q value based on Chi squared statistics
Fig. 2Summary of meta-analyses for associations between previously implicated lipid loci and cardio-metabolic traits. There are genes and genetic loci on chromosomes associated with cardio-metabolic traits that reached the statistical significance (P < 3.70 × 10−4) after correction for multiple testing in this study
Pleiotropic effects of three SNPs located in the 12q24.12 region
| Traits | n | rs671, | rs11066015, | rs3782886, | |||
|---|---|---|---|---|---|---|---|
| Effect size (beta ± s.e.) |
| Effect size (beta ± s.e.) |
| Effect size (beta ± s.e.) |
| ||
| Lipids | |||||||
| TC | 13,378 | −0.03 ± 0.59 | 0.9547 | −0.03 ± 0.59 | 0.9633 | −0.26 ± 0.58 | 0.6502 |
| TG | 13,378 | −7.60 ± 1.72 | 9.47 × 10−6 | −7.28 ± 1.71 | 2.11 × 10−5 | −6.93 ± 1.68 | 3.53 × 10−5 |
| LDL | 13,378 | 2.55 ± 0.53 | 1.53 × 10−6 | 2.54 ± 0.53 | 1.50 × 10−6 | 2.13 ± 0.52 | 3.80 × 10−5 |
| HDL | 13,378 | −1.33 ± 0.18 | 1.20 × 10−13 | −1.33 ± 0.18 | 7.61 × 10−14 | −1.33 ± 0.17 | 2.97 × 10−14 |
| Blood pressure | |||||||
| SBP | 10,310 | −1.49 ± 0.32 | 2.72 × 10−6 | −1.53 ± 0.32 | 1.33 × 10−6 | −1.34 ± 0.31 | 1.50 × 10−5 |
| DBP | 10,310 | −0.80 ± 0.21 | 1.09 × 10−4 | −0.82 ± 0.21 | 7.12 × 10−5 | −0.78 ± 0.20 | 1.02 × 10−4 |
| Glycemic traits | |||||||
| FPG | 13,378 | −0.96 ± 0.17 | 2.00 × 10−8 | −0.92 ± 0.17 | 5.93 × 10−8 | −0.90 ± 0.17 | 7.21 × 10−8 |
| HbA1c | 7524 | 0.003 ± 0.008 | 0.6858 | 0.006 ± 0.008 | 0.4870 | 0.004 ± 0.008 | 0.5924 |
| Obesity | |||||||
| BMI | 13,378 | −0.16 ± 0.05 | 2.14 × 10−3 | −0.16 ± 0.05 | 2.10 × 10−3 | −0.13 ± 0.05 | 1.06 × 10−2 |
| WHR | 13,378 | −0.005 ± 0.001 | 2.87 × 10−6 | −0.005 ± 0.001 | 3.35 × 10−6 | −0.004 ± 0.001 | 3.45 × 10−5 |
n number of participants, s.e. standard error, TG Triglyceride, TC Total cholesterol, LDL Low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c Glycated hemoglobin, BMI body mass index, WHR waist-hip ratio
All of analyses were adjusted by age and sex
Evaluation of pleiotropic effect of 12q24.12 (ALDH2, rs671) genotypes
| Trait | Effect size(beta ± s.e.) |
| After adjustment for an additional covariate | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TG | LDL | HDL | FPG | |||||||
| Effect size |
| Effect size |
| Effect size |
| Effect size |
| |||
| TG | −7.60 ± 1.72 | 9.47 × 10−6 | – | – | −4.34 ± 1.18 | 2.44 × 10−4 | −12.24 ± 1.64 | 8.41 × 10−14 | −6.34 ± 1.68 | 1.58 × 10−4 |
| LDL | 2.55 ± 0.53 | 1.53 × 10−6 | 2.42 ± 0.54 | 7.47 × 10−6 | – | – | 2.76 ± 0.54 | 3.24 × 10−7 | 2.97 ± 0.56 | 9.78 × 10−8 |
| HDL | −1.33 ± 0.18 | 1.20 × 10−13 | −1.70 ± 0.18 | 1.80 × 10−21 | −1.53 ± 0.19 | 8.14 × 10−16 | – | – | −1.42 ± 0.19 | 8.88 × 10−14 |
| FPG | −0.96 ± 0.17 | 2.00 × 10−8 | −0.96 ± 0.19 | 2.00 × 10−7 | −1.11 ± 0.18 | 1.85 × 10−9 | −0.96 ± 0.19 | 2.38 × 10−7 | – | – |
| SBP | −1.49 ± 0.32 | 2.72 × 10−6 | −1.25 ± 0.33 | 1.37 × 10−4 | −1.45 ± 0.33 | 1.26 × 10−5 | −1.50 ± 0.33 | 5.68 × 10−6 | −1.09 ± 0.34 | 1.14 × 10−3 |
| DBP | −0.80 ± 0.21 | 1.09 × 10−4 | −0.67 ± 0.21 | 1.41 × 10−3 | −0.83 ± 0.21 | 1.03 × 10−4 | −0.90 ± 0.21 | 2.35 × 10−5 | −0.66 ± 0.22 | 2.35 × 10−3 |
| BMI | −0.16 ± 0.05 | 2.14 × 10−3 | −0.11 ± 0.05 | 2.90 × 10−2 | −0.20 ± 0.05 | 1.45 × 10−4 | −0.26 ± 0.05 | 3.86 × 10−7 | −0.14 ± 0.05 | 1.14 × 10−2 |
| WHR | −0.005 ± 0.001 | 2.87 × 10−6 | −0.004 ± 0.001 | 2.81 × 10−4 | −0.005 ± 0.001 | 1.92 × 10−5 | −0.007 ± 0.001 | 1.48 × 10−10 | −0.004 ± 0.001 | 3.54 × 10−4 |
Total cholesterol was excluded from this analysis. n = 13,378 for all traits except SBP and DBP, where n = 10,310
TG Triglyceride, LDL low density lipoprotein cholesterol, HDL high density lipoprotein cholesterol, FPG fasting plasma glucose, SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, WHR waist-hip ratio, s.e. standard error
Fig. 3Pleiotropic effects on three genes (BRAP, ACAD10 and ALDH2) in the 12q24.12 region. This region was associated independently with each cardio-metabolic trait according to additional analyses including adjustments. The black arrows represented the direction of genetic effects on each trait
Pleiotropic association between lipid risk scores and cardio-metabolic traits
| Lipid RS | SBP | DBP | FPG | BMI | WHR | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Effect size |
| Effect size |
| Effect size |
| Effect size |
| Effect size |
| |
| LDL_RS | −0.24 ± 0.07 | 2.87 × 10−4 | −0.12 ± 0.04 | 3.82 × 10−3 | −0.17 ± 0.04 | 2.43 × 10−6 | −0.02 ± 0.01 | 0.085 | −0.0006 ± 0.0002 | 8.55 × 10−3 |
| HDL_RS | −0.32 ± 0.07 | 9.05 × 10−6 | −0.15 ± 0.05 | 1.54 × 10−3 | −0.18 ± 0.04 | 7.17 × 10−6 | −0.02 ± 0.01 | 0.165 | −0.0004 ± 0.0002 | 0.113 |
| TG_RS | −0.20 ± 0.07 | 5.57 × 10−3 | −0.07 ± 0.05 | 0.103 | −0.19 ± 0.04 | 1.55 × 10−6 | −0.02 ± 0.01 | 0.160 | −0.0007 ± 0.0002 | 2.07 × 10−3 |
| TC_RS | 0.08 ± 0.10 | 0.457 | 0.03 ± 0.07 | 0.623 | 0.26 ± 0.06 | 3.27 × 10−6 | 0.04 ± 0.02 | 6.21 × 10−3 | 0.0010 ± 0.0003 | 2.52 × 10−3 |
| wLDL_RS | −0.04 ± 0.02 | 3.03 × 10−2 | −0.04 ± 0.01 | 4.95 × 10−3 | −0.06 ± 0.01 | 1.59 × 10−7 | −0.02 ± 0.00 | 5.77 × 10−9 | −0.0003 ± 0.0001 | 2.69 × 10−5 |
| wHDL_RS | 0.18 ± 0.05 | 4.42 × 10−4 | 0.17 ± 0.03 | 1.45 × 10−7 | 0.02 ± 0.03 | 0.396 | 0.07 ± 0.01 | 1.44 × 10−18 | 0.0017 ± 0.0002 | 8.11 × 10−25 |
| wTG_RS | 0.02 ± 0.01 | 0.070 | 0.01 ± 0.01 | 0.161 | −0.01 ± 0.005 | 0.237 | −0.003 ± 0.001 | 1.73 × 10−2 | −0.00001 ± 0.00003 | 0.798 |
| wTC_RS | −0.03 ± 0.02 | 0.183 | −0.02 ± 0.01 | 0.125 | −0.08 ± 0.01 | 2.32 × 10−10 | −0.02 ± 0.004 | 1.55 × 10−6 | −0.0002 ± 0.0001 | 8.87 × 10−3 |
Lipid RS lipid risk score, LDL_RS unweighted LDL risk score, HDL_RS unweighted HDL risk score, TG_RS unweighted TG risk score, TC_RS unweighted TC risk score, wLDL_RS weighted LDL risk score, wHDL_RS weighted HDL risk score, wTG_RS weighted TG risk score, wTC_RS weighted TC risk score, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, BMI body mass index, WHR waist-hip ratio
Effect size are shown as beta ± standard error. All of analyses were adjusted by age, sex and lipids